Incidence of Liver Damage with Tigecycline
Tigecycline, a glycylcycline antibiotic used for complicated infections, causes liver enzyme elevations in about 20-30% of adults, based on clinical trials and post-marketing data. Direct hepatotoxicity (e.g., elevated ALT/AST >3x upper limit of normal) occurs in 2-15% of patients, with rates varying by dose, duration, and patient factors like baseline liver function.[1][2]
Key Clinical Trial Data
In phase 3 trials for skin/soft tissue infections and intra-abdominal infections (n>1,600 adults), hepatic adverse events hit 25% overall:
- ALT elevation: 13-20%
- AST elevation: 12-15%
- Serious liver injury (e.g., bilirubin >2x ULN with transaminases >3x ULN): <1%, mostly reversible.[3]
Pooled analysis shows higher rates (up to 26%) with 100mg loading dose followed by 50mg twice daily versus comparators like vancomycin (15%).[1]
Real-World Frequency and Risk Factors
Post-approval surveillance reports hepatotoxicity in 1-5% of cases, including rare acute liver failure (0.1-0.5%).[4] Risks rise with:
- Prolonged use (>14 days): enzyme elevations double.
- Comorbidities: obesity, diabetes, or alcohol use increase odds by 2-3x.
- Concomitant drugs: statins or other hepatotoxins amplify effects.
FDA labeling notes "hepatic laboratory test abnormalities" as common (≥5%), with monitoring advised.[5]
How Tigecycline Causes Liver Damage
It disrupts mitochondrial function in hepatocytes, leading to oxidative stress and enzyme leaks. Unlike other tetracyclines, tigecycline's biliary excretion (59%) concentrates it in the liver, heightening toxicity. Most cases are asymptomatic and resolve post-discontinuation (median 10-20 days).[2][6]
Comparison to Other Antibiotics
Tigecycline's liver effects exceed vancomycin (10-15%) and linezolid (5-10%) but match some carbapenems (15-20%). It's riskier than standard tetracyclines (e.g., doxycycline <5%).[1][3]
When Does Liver Damage Appear and Resolve?
Onset typically 5-14 days into therapy; peaks at 2-4 weeks. Resolution occurs in 80-90% within 1-2 months after stopping, though 5-10% persist or recur.[4]
Monitoring and Patient Concerns
Guidelines recommend baseline LFTs, weekly checks during treatment, and discontinuation if ALT >5x ULN. Patients report jaundice or fatigue in severe cases; black-box warnings highlight mortality risk in ventilator-associated pneumonia, partly linked to hepatic issues.[5]
[1]: DrugPatentWatch.com - Tigecycline Safety Data
[2]: FDA Tygacil Label (2010 update)
[3]: Meagher et al., Clin Infect Dis (2005); Pooled phase 3 analysis
[4]: LiverTox NIH Database - Tigecycline
[5]: FDA Adverse Event Reporting System (FAERS) summaries
[6]: Muralidharan et al., Antimicrob Agents Chemother (2005)